Riociguat Accord (riociguat)

Where it stands

Riociguat Accord (riociguat), from Accord Healthcare S.L.U., received a positive CHMP opinion on 23 July 2026. The records show its status as "Opinion", with no approval date yet. The European Commission (EC) has not issued its decision.

The proposed indication is the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) in adults, and of pulmonary arterial hypertension (PAH) in adults and children from 6 years of age. The therapeutic area is recorded as Hypertension, Pulmonary and Pulmonary Arterial Hypertension.

The records give an expected EC decision date of 28 September 2026. This is an estimate, calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. It is not an official date and could move.

Regulatory pathway and designations

The only designation recorded is "Generic". A CHMP positive opinion is a scientific recommendation to grant a marketing authorisation. It becomes legally binding in the EU only once the EC adopts its decision, which normally follows the opinion by about two months.

The same substance is already authorised in the EU as Adempas (riociguat). In general, a generic application builds on an authorised reference medicine and relies on demonstrated equivalence rather than a full new clinical programme. The records do not name the reference product, the legal basis of the application, or any bioequivalence data, so those points cannot be confirmed here.

The records show no orphan, PRIME, conditional approval or other special designations or pathways for this product.

Safety and pharmacovigilance

The records contain no safety information for Riociguat Accord. This includes warnings, contraindications, risk management plan content, additional monitoring status and any post-authorisation commitments.

Generics are generally expected to carry product information consistent with their reference medicine. Any specific safety conclusions should be checked against the CHMP's published assessment documents and the final EC-approved product information once available.

What to watch

The key event is the EC decision, estimated for around 28 September 2026. Confirmation of the actual decision date, and publication of the final product information, would show whether the full indication, including children from 6 years of age, is authorised as proposed.

Further developments to follow include the CHMP's public assessment report, the approved product information and any commercial launch timing. Launch timing is not covered in the records. The existing authorisation of Adempas is the relevant comparator for the EU riociguat market.